Robotic Phlebotomy * AI Guided Vein Access

The blood draw, reinvented

A human-assisted robotic device that combines ultrasound imaging and AI to see beneath the skin, map the vein, and guide the needle so every stick is precise, painless, and repeatable.

Investigational device. Limited by federal law to investigational use. This system is a working prototype and is not cleared by the FDA or any other regulatory authority for commercial sale or clinical use outside of authorized clinical investigations.

Predict the future

Labor shortage is putting significant strain on the industry

$1.2B+

5 million

1 in 5

Failed sticks / year

Annual US cost

Donors quit

30%

Phlebotomist attrition

Engineered for Precision

By automating repetitive mechanical tasks, our device helps healthcare networks address staffing shortages while reducing human variability. It delivers consistent workflows and upholds the highest standards of safety and quality.

Ultrasound Imaging

Real-time vessel visualization beneath the skin's surface

AI / ML Detection

Speed of Assessment

Instinctive Workflow

Faster than manual palpation – vein identified before needle is uncapped

Machine learning maps vein location, diameter, and depth automatically

Designed for any phlebotomist or technician skill level

Our Solution

AI-Enabled Robotic Healthcare Automation

Who we are: ROPHAI is a medtech spin-off developing a robotic, AI-enabled phlebotomy device.

Massive underserved market: Venipuncture (blood draw) is the most common clinical procedure in the world — over 1 billion procedures globally and more than 400 million in the US alone every year. Phlebotomy roles see ~30% turnover. US Bureau of Labor Statistics projects ~10% demand growth through 2031 — a structural shortage hitting high-volume plasma and blood donation centers hardest.

Our solution: Our device automates venipuncture with consistent, repeatable performance, starting in plasma & blood donation centers, expanding to diagnostic labs, hospitals, and pharmacies.

De-risked technology: Over many years and millions+ invested in R&D, with a working prototype validated on hundreds of donors/patients.

IP protected: Licensed patent portfolio (granted and pending).

Clear path to market: Raising Series A funding to complete FDA clearance, with follow-on funding to launch commercialization.

Current stage & milestone roadmap: We have successfully developed a fully functional engineering prototype of our device. Having achieved robust benchtop and preclinical performance milestones ROPHAI is currently executing its regulatory preparation phase. Our primary objective for our upcoming Series A financing round is to fund the initiation of human clinical trials. The data gathered from these upcoming clinical evaluations is intended to support our formal submission for FDA premarket clearance. We have active FDA engagement, De Novo pathway, and alignment on feasibility & clinical trial protocol.